莱姆病自1986年首次确诊以来,已在中国29个省份得到临床诊断,缺乏全国发病率数据。总结中国各地人群的莱姆病血清阳性数据,我们对2005-2020年期间发表的中文和英文期刊文章进行了系统的文献综述。根据72估计,仅使用诊断酶联测定法(EIA)测量IgG,固定效应模型的血清阳性点患病率为9.1%.EIA的更保守的2层测试方法加上验证性Western免疫印迹(16个估计值)产生了1.8%的血清阳性。EIA对高风险暴露人群的血清阳性率为10.0%,对低风险暴露人群的血清阳性率为4.5%;东北和西部省份的血清阳性率最高。我们的分析证实了莱姆病的患病率,以血清阳性衡量,在许多中国省份和处于危险之中的人群中。该信息可用于将预防措施集中在血清阳性较高的省份。
Since its initial identification in 1986, Lyme disease has been clinically diagnosed in 29 provinces in China; however, national incidence data are lacking. To summarize Lyme disease seropositivity data among persons across China, we conducted a systematic literature
review of Chinese- and English-language journal articles published during 2005‒2020. According to 72 estimates that measured IgG by using a diagnostic enzyme-linked assay (EIA) alone, the seropositivity point prevalence with a fixed-effects model was 9.1%. A more conservative 2-tier testing approach of EIA plus a confirmatory Western immunoblot (16 estimates) yielded seropositivity 1.8%. Seropositivity by EIA for high-risk exposure populations was 10.0% and for low-risk exposure populations was 4.5%; seropositivity was highest in the northeastern and western provinces. Our analysis confirms Lyme disease prevalence, measured by seropositivity, in many Chinese provinces and populations at risk. This information can be used to focus prevention measures in provinces where seropositivity is high.